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Abstract
Objective—Low androgen levels occur in women with primary ovarian insufficiency(POI) and
could contribute to mood and behavioral symptoms in this condition. We examined the effects of
physiologic testosterone (T) replacement therapy added to standard estrogen/progestin
replacement therapy (EPT) on quality of life, self-esteem, and mood in women with POI.
Methods—128 women with 46XX spontaneous POI participated in a 12 month randomized,
placebo-controlled, parallel-design investigation of the efficacy of T augmentation of EPT.
Quality of life, self-esteem, and mood symptoms were evaluated with standardized rating scales
and a structured clinical interview. Differences in outcome measures between the T and placebo
treatments were analyzed by Wilcoxon rank-sum tests.
Results—No differences were found in baseline characteristics including serum hormone
levels(P >0.05). Baseline mean(SD) CES-D scores were 10.7(8.6)(T) and 9.2(7.8)(placebo) (P =
0.35). After 12 months of treatment, measures of quality of life, self-esteem, and the presence of
mood symptoms did not differ between treatment groups. Serum T levels achieved physiologic
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levels in the T group and were significantly higher compared to placebo (P < 0.001). Baseline T
levels were not associated with either adverse or beneficial clinical effects.
Conclusions—The 150 microgram T patch achieves physiologic hormone levels in women with
POI. Our findings suggest that augmentation of standard EPT with physiologic testosterone
replacement in young women with POI neither aggravates nor improves baseline reports of quality
of life, or self-esteem and had minimal effect on mood. Other mechanisms might play a role in the
altered mood that accompanies this disorder.
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Introduction
Primary ovarian insufficiency (POI) affects approximately 1% of women before age 40, and
is accompanied by infertility, decreased quality of life, depression, increased risk for
osteoporosis and cardiovascular disease (1–5). In addition to decreased ovarian estradiol and
progesterone production, women with POI have lower circulating levels of androgens
compared with women who have normal ovarian function (6–9). Total production of
testosterone (T) in women is estimated to be approximately 300 mcg per day with ovarian
production of T accounting for approximately 50% of this total daily secretion and, in
women with POI, there is considerable evidence suggesting that ovarian T production is
insufficient. Current hormone replacement strategies were developed for women who
experience natural menopause at an average age of 50. However, despite the large number
of studies on hormone therapy in normally menopausal women, less is known about the
effects of menopausal hormone therapy on ovarian failure in young women. Women with
POI will take estrogen replacement for decades and the potential long-term sequelae of
prolonged reduced serum T levels in these women are unknown. Thus, our overall goal was
to examine the effects (both beneficial and adverse) on quality of life, mood, and self-
esteem, after the restoration of normal circulating levels of T in young women with POI.
Specifically, this study was designed to neither examine the effects of pharmacologic doses
of T on these behavioral measures, nor to specifically test the efficacy of physiologic T
replacement on depressive symptoms in these women. Young women with androgen
deficiency may experience a variety of physical symptoms secondary to their androgen
depletion as well as psychological changes that affect their quality of life (1). Androgen
deficiency in women could contribute to depressed mood and reduced quality of life (10, 11)
and T replacement has been recommended in some women with POI who present with
decreased well-being, persistent fatigue and low libido despite adequate estrogen
replacement (12). Studies also demonstrate the beneficial effects of androgen therapy on
mood and libido in hypogonadal women with a surgically-induced menopause, a concurrent
medical or psychiatric illness (e.g., HIV and anorexia nervosa, respectively), or reproductive
aging (13–18). A recent study also reported the beneficial effects of T replacement under
placebo-controlled conditions on quality of life in women with Turner syndrome who, like
women with POI, experience ovarian insufficiency (19). Finally, physiologic T replacement
has been reported to improve mood in women with anorexia nervosa (18). Nonetheless,
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some studies suggest that T replacement could negatively impact on mood and behavior
(20–22), and, therefore, the evaluation of its effects in these women is warranted. However,
there are less data available on the effects of T on quality of life and mood in young
hypogonadal with POI. As part of a 3-year placebo controlled trial examining the effects of
the addition of T to combined estrogen and progesterone therapy (EPT) on measures of bone
density in POI, we examined the effect of adding the ovarian production rate of T on
measures of quality of life, self-esteem, and depressive symptom severity in 128 women
with spontaneous 46, XX POI.
Material and Methods
Participant Selection
Women between the ages of 18 and 42 years participated in this National Institute of Child
Health and Human Development (NICHD) study at the NIH Clinical Research Center from
2000 to 2006. This study was part of a larger three-year randomized, controlled trial,
investigating the effects of testosterone augmentation of a combined EPT regimen on
measures of bone density (6). Participants were recruited through notices on the NIH home
page or physician referral, and each woman provided written informed consent for
participation in this IRB-approved protocol. The diagnosis of POI for this study was based
on a history of at least four months of non-iatrogenic oligo-amenorrhea occurring in women
< 40 years of age and at least two determinations of menopausal serum FSH levels (> 40
mIU/ml) with a normal, 46, XX peripheral karyotype. Participants with baseline serum free
testosterone levels above 3.1 pg/mL or sex hormone binding globulin (SHBG) levels less
than 36 nmol/L were excluded from the study. Additional exclusions included current
smokers (> 2 cigarettes per day), those consuming more than two alcoholic beverages daily,
and those with a BMI > 30 or < 19, or a hirsutism score > 8 (23). Medical histories, physical
and gynecologic exams and psychiatric evaluations were then performed, after which
women were offered participation in the trial of T replacement therapy in addition to
standard EPT. After randomization, each woman was evaluated at 3 and 12 months after
which their participation in this component of the trial was complete. Participants with
current major depression or those on antidepressant therapy were not excluded from
participation. Women who met criteria for depression on admission were offered standard
antidepressant therapy by either their primary treating physician or an NIH physician re-
evaluation prior to entering this trial. The dose or type of antidepressant was not altered in
any woman during the 1 year trial (unless they wished to stop the medicine altogether).
Study Design and Procedures
This was a randomized, double blind, placebo-controlled, parallel design trial in which we
evaluated measures of quality of life, self-esteem, and depressive symptoms for one year to
examine the efficacy of physiologic T replacement in EPT (see CONSORT checklist,
Supplemental Digital Content 1). This trial was part of a 3-year study that focused on bone
density as the primary outcome in women with POI. After screening, all participants
initiated three months of EPT to ensure that all women began the study on a standardized
EPT regimen While continuing EPT, all women were randomized to one of two groups; a
group consisting of EPT with placebo patch and a group consisting of EPT with testosterone
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patch EPT consisted of 100 micrograms daily transdermal estradiol (Watson Laboratories,
Salt Lake City, UT) with oral medroxyprogesterone acetate (10 milligrams daily for 12 days
of each 28 day cycle). The dosage of T was 150 micrograms per day administered
transdermally (Watson Laboratories, Salt Lake City). The NIH pharmacy generated
sequentially numbered patches containing either testosterone or placebo and provided that
randomization number with the study medication on the day of admission. Study
participants and all raters were blinded to the intervention assignment and did not have
access to lab results or rating scale scores from of prior clinic visits.
Outcome Measures
Symptom ratings and blood hormone levels were obtained at three time points as follows: at
baseline prior to randomization, and at three and 12 months after initiation of T or placebo.
Outcome measures for this trial were both self- and rater-administered, and included the 14-
item Quality of Life Enjoyment and Satisfaction Questionnaire (Q-Les-Q) (24) and the 10-
item Rosenberg Self-Esteem Scale (25) in which higher scores reflect better self-esteem and
quality of life, respectively. We employed the Structured Clinical Interview for the
Diagnostic and Statistical Manual of Mental Disorders (fourth edition) [DSM-IV] (SCID)
(26) to establish the presence or absence of Axis I psychiatric illness, as well as the self-
administered Center for Epidemiologic Studies Depression Scale (CES-D) (27) and the
rater-administered Hamilton Rating Scale for Depression (HAM-D) (28) which assess
depressive symptom severity. Blood samples for hormone assays were obtained from fasting
women at 0800 h, separated within one hour, and frozen at −70 degrees C until the time of
assay.
Hormonal Assays
Serum measurements of total testosterone (reference range 14–54.3 ng/dl) were made using
radioimmunoassay (RIA) after extraction chromatography (Esoterix Endocrinology,
Calabassa Hills, CA). Serum free testosterone (reference range 1.3–6.8 pg/ml) was
determined with equilibrium dialysis (8) and was calculated from the ratio of radioactivity
outside versus inside the cell multiplied by the total serum testosterone. Serum estradiol,
FSH, and LH levels were performed at the NIH Clinical Center laboratory. Estradiol was
measured by a competitive chemiluminescence immunoassay (Immulite 2000) and
microparticle enzyme immunoassay (AxSYM System, Abbott Diagnostics, Abbott Park, IL)
was used to measure FSH and LH. Serum SHBG was measured with an immunoradiometric
assay (IRMA) developed at Esoterix Endocrinology (Calabasas Hills, CA). The serum
hormone intra-assay and inter-assay coefficients of variation (CV) are as follows: total
testosterone (intra-assay CV = 2.9% – 8.0%; inter-assay CV = 8.0%–15.0%), free
testosterone (intra-assay CV = 6.9%; inter-assay CV = 8.9–9.4%), estradiol (both intra-assay
and inter-assay CV were < 11.0%), FSH (intra-assay CV was 4.9%; inter-assay CV was
6.5%) and LH (intra-assay CV = 5.8%; and inter-assay CV = 6.4%), and SHBG (intra-assay
CV = 2.4%–3.9%; inter-assay CV = 7.8% – 10.6%).
Statistical Analysis
All data were analyzed using SAS Version 9.2 statistical software (SAS Institute, Inc, Cary,
NC). Baseline characteristics in women receiving T and those receiving placebo were
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compared with Fisher’s exact test for categorical variables and Wilcoxon rank-sum tests for
continuous variables. Wilcoxon rank-sum tests were employed to compare the symptom
rating scale scores and serum hormone levels of women randomized to receive T and those
randomized to receive placebo. The values at each clinic visit (i.e., baseline, month 3, and
month 12), as well as the differences in values between baseline and three months, and
between baseline and 12 months were included in the analyses.
Additionally, we compared the numbers of women on T compared with placebo who met
SCID criteria for major depression as well as the numbers who met criteria for either
clinically significant depressive symptoms (defined as CES-D scores ≥ 16 (29–31)) or
subsyndromal depression (defined as CES-D scores ≥ 8 and ≤16 (32, 33)), at each time point
using Fisher’s exact test. We also used the Fisher’s exact test to compare the numbers of
women in each treatment group who experienced a 50% or greater improvement (i.e.,
reduction) in their CES-D scale scores at 12 months compared with baseline. Results were
presented as mean (SD) for interval data and counts and percentages for nominal and ordinal
data. Because of the presence of missing data, we also performed a separate repeated
measures analysis for each of the four symptom rating scores using SAS’s PROC MIXED,
comparing the T and placebo treatment groups at 3-months and 12-months. The predictor
variable of interest (treatment) and month were modeled as fixed effects. The interaction
term of month*treatment was not significant and was therefore dropped from the final
models. We included the baseline symptom rating as a covariate and used a covariance
structure of compound symmetry, with the Kenward and Roger method for computing the
degrees of freedom. The power analysis for this study was based on the larger, 3-year study
on bone density outcomes; whereby, using a power level of 0.90 and an alpha level of 0.05,
a sample size of 50 women in each group was estimated to be required to detect a difference
in bone mineral density related to the addition of testosterone. All P values were two tailed
with a P < 0.05 considered significant.
Results
Baseline Characteristics
Of the 395 women with POI who were assessed for eligibility, 128 women (age range 19–41
years, mean age (31.6) were randomized into either T-treatment (n = 67) or placebo (n = 61)
and 123 women completed this study (Figure 1). There was no group difference between the
ages of women randomized to receive T (mean (SD) = 31.1 (5.8) years) and those
randomized to receive placebo (mean 32.1 (5.5) years) nor were there group differences in
the BMI of the women randomized to receive T (mean (SD) = 23.4 (3.3)) or placebo (mean
(SD) = 24.2 (3.2)) or in the number of women with POI who were treated for a thyroid
condition (n = 5, and 6 in T and placebo groups, respectively) (P = NS for all comparisons).
Additionally, no differences were observed between groups in baseline serum free
testosterone (P = 0.7) or total testosterone measures (P = 0.2). (Table 1).
Similarly, there were no significant differences between the T treatment and placebo groups
in the numbers of women meeting criteria for either major depression or subsyndromal
depression at baseline. Eight women in each arm met SCID criteria for major depression
(11.9% in T treatment and 13.1% in placebo groups [P = NS]), while 4.5% (n = 3) and
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11.5% (n = 7 [P = NS]) women in the T and placebo groups, respectively, met criteria for
current minor depression. Baseline CES-D scores did not differ between those women
randomized to T and those randomized to placebo (P = NS). No group differences were
observed in the number of women who met baseline CES-D criteria for clinically significant
depressive symptoms (i.e., a CES-D score ≥ 16), with 15 (22.4%) in the T arm and 7
(11.7%) in the placebo arm meeting this threshold value (P = 0.16); nor were group
differences observed in the number of women who met criteria for subsyndromal depression
(26 (38.8%) in the T and 23 (37.7%) in the placebo groups). A history of past major
depression was diagnosed by SCID interview in thirty-three women in both the T treatment
arm (49%) and placebo arm (54.1%). Eighty-five women had no lifetime DSM-IV axis-I
mood disorder diagnosis (n = 43 in T, n = 42 in placebo groups respectively) (P = NS for all
comparisons). Finally, a similar number of women currently receiving antidepressant
treatment were randomized to T treatment (18% (n = 12) and placebo (19% n = 11) (P =
NS). Of the 128 enrolled participants, 123 completed the study (Figure 1).
Treatment Trial
Symptom Rating Scores (Table 2)—We found no differences in either the Q-Les-Q or
Rosenberg self-esteem scale scores in women randomized to T or placebo at baseline (P =
0.4 and 0.7, respectively), at three months (P = 0.3 and 0.8, respectively) or after 12 months
of treatment (P = 0.2 and 0.9, respectively).
Mood rating scale scores and syndromal measures of depression did not differ across
treatment groups after 12 months. No significant differences were observed in either the
CES-D scores or the change from baseline in CES-D scores between women randomized to
T treatment or placebo after three months or 12 months of treatment (P = NS for all
comparisons). Similarly, no differences were observed in the numbers of women with CES-
D scores ≥ 16 at either the three or 12 month visits (P = 1.0, and 0.2, respectively) or the
numbers of women with CES-D scores ≥ 8 and <16 at either the three or 12 month visits (P
= 1.0 and 0.66, respectively). Finally, the number of women who experienced a 50% or
greater reduction in CES-D scores after 12 months was no different in the T-treatment group
compared with placebo-treated women (n = 28 (50.9%) and n = 19 (36.5%) in T and
placebo, respectively, (P = 0.2)).
A similar pattern was observed in the effects of T and placebo treatments on HAM-D scores.
No group differences were observed in HAM-D rating scale scores between T treatment and
placebo at baseline (P = 0.4), nor were treatment-related differences observed in either the
scores at three months (P = 0.7) and 12 months (P = 0.1) or the change in scores at three
months (P = 0.4) and 12 months (P = 0.8). Similarly, no differences were observed in the
number of women who met SCID criteria for major depression across treatment groups at
three months (P = 1.0) or 12 months (P = 0.5). Additionally, in the sample of women who
were not depressed at baseline (i.e., women who met SCID criteria for depression were
excluded), no differences were observed in CES-D scores between the numbers of women
who were randomized to T (N =59) and placebo (N = 52) treatment at 3 months or 12
months (P =0.8 and P =0.6, respectively). Finally, we found no differences in measures of
either Q-Les-Q or Rosenberg self-esteem scores at 3 months or 12 months (P=NS for all
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comparisons) among women randomized to T and placebo who were not depressed at
baseline (either by SCID diagnosis or by CES-D scores for syndromal symptoms of
depression).
Adverse Effects (Table 3)—No negative effects on mood were uniformly observed
between groups. Indeed, no women in either treatment group dropped out of the study
because of negative mood symptoms. Five women from the T treatment arm dropped out of
the study after three months, two of whom reported skin irritation or rash while the other
three were lost to follow-up. Of those five women, four had nearly identical CES-D and
HAM-D scores at baseline and at three-months with no score > 9 on either measure. One
woman reported a reduction in depressive symptoms in both CES-D and HAM-D scores
from baseline (19 and 27, respectively) to three months (3 and 4, respectively) and
discontinued the trial due to the development of a rash. Androgenic side effects were also
reported by several women in the trial but these side effects were infrequent and did not
significantly differ between treatment groups.
Serum Hormone Levels (Table 4)—Significant differences were found in serum total
testosterone levels among women with POI receiving T treatment, compared with placebo
after three months and at 12 months (P < 0.001 for both groups at each time interval
respectively). Similarly, significant differences were observed in free testosterone levels
among women receiving T treatment, compared with placebo after both three and 12 months
(P < 0.001 for both groups respectively). In contrast, no group differences were observed in
serum measures of estradiol, FSH, LH or SHBG at baseline, three months or at 12 months (P
= NS for all comparisons).
Discussion
This is the first large scale study to evaluate the effects of physiologic T replacement with
EPT on measures of quality of life and depressive symptoms in a sample of women with
well characterized POI. T replacement had neither detrimental nor beneficial effects,
compared to placebo, on measures of quality of life, self-esteem, and several measures of
mood. Despite significant elevations of serum T levels during treatment, we did not observe
significant improvements compared to placebo in any of the behavioral outcomes we
measured. A considerable number of women in both treatment groups met criteria for either
subsyndromal or syndromal depression (i.e., 61.2% and 50.0 % in T and placebo,
respectively); nonetheless, only a small number of women in this study met criteria for
major depression, most of whom received concurrent use of antidepressant medications.
Thus the results of this study cannot be interpreted to define the efficacy of T replacement in
women with POI who have major depression. Albeit indirect, evidence of the failure of T to
significantly improve mood may suggest that depressive symptoms in women with POI are
androgen independent, and perhaps related to other environmental or reproductive factors
experienced by these women.
Our finding that T augmentation of EPT was no more effective than EPT alone on measures
of quality of life and mood is consistent with some but not all studies. Indeed, overall the
results of studies examining the effects of T replacement in addition to estrogen therapy on
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mood and well-being are mixed. In ostensibly the same study, Sherwin and Gelfand (34, 35)
compared the effects of intramuscular preparations of estrogens with and without androgen
augmentation on symptoms of depression and well-being in women who had undergone a
surgical menopause. Improvements in symptoms were observed relative to baseline with
both estrogen alone and estrogen/androgen preparations; however, depression measures did
not differ between women receiving combined estrogen/androgen and those receiving
estrogens alone, whereas feelings of well-being were significantly higher in those women
treated with the addition of T replacement. Mood enhancement also was reported using oral
preparations of estrogen and testosterone in postmenopausal (36) and oophorectomized
women (37), respectively. As in our study, most of the women in these negative trials were
recruited because they were hypogonadal but not necessarily symptomatic, and therefore,
baseline levels of mood and quality of life could have been too high or too low, respectively
to show a beneficial effect of T treatment. Several studies have reported benefits of T
replacement in hypogonadal women (after oophorectomy), whose selection for entry into the
trials was based on their complaints of clinically significant loss of sexual function (38–41).
In the study by Shifren et al.(40), significant differences between T and placebo in measures
of mood were only observed in women taking a higher dose of transdermal T (i.e., 300
micrograms per day), but not in those receiving a dose equivalent to that employed in this
trial. Thus it is possible that had we selected more symptomatic women with POI, or
employed higher doses of transdermal T, a more robust difference in mood measures or
quality of life would have been observed in our study. Nonetheless, physiologic doses of T
replacement were observed to improve mood in a group of women with anorexia nervosa in
whom depression rating scale scores were consistent with clinically significant depression
(i.e., Beck Depression Inventory ≥ 10) in approximately 50% of the sample (18). Women
with POI differ from women who have undergone a surgical menopause in several clinical
characteristics including the early age of onset of ovarian insufficiency, the impact on
potential fertility, and frequency of vasomotor symptoms. Thus, a better comparison group
is women with Turner Syndrome (TS), who also experience ovarian insufficiency from an
early age. Indeed, in a prior study we observed similar levels of anxiety, shyness, and low
self-esteem in women with TS and POI, both groups being more symptomatic than a healthy
comparison group (4). There has been one placebo-controlled trial of T replacement in
addition to estrogen therapy in women with TS (19). In this study, quality of life measures
improved on 1.5 mg a day of methyltestosterone compared with placebo, as did several
metabolic, cognitive, and sexual function measures. However, as with some studies in
women who had undergone a surgical menopause, the women with TS were taking oral
estrogens and had lower baseline free T levels than the women in this study (i.e., mean free
T levels at baseline were 1.1 pg/ml vs 2.2 pg/ml respectively). The dose of T employed in
the women with TS was 1.5 mg of methyltestosterone, and, therefore, also could have been
supraphysiologic compared to the doses we employed. Overall, our findings of a lack of
efficacy of physiologic low dose testosterone addition to estrogen therapy are consistent
with several previous studies in hypogonadal women and do not support the routine use of T
to improve mood symptoms in women with POI. However, we cannot rule out the
possibility that the selection of more symptomatic women or those with lower baseline T
levels, or the use of higher doses of T, would result in a more robust pattern of effects of T
on mood symptoms, quality of life, and self-esteem measures.
Guerrieri et al. Page 8






















A recent meta-analysis supported several reports that POI was accompanied by low
testosterone levels compared with healthy young women (9). Evidence of testosterone’s
beneficial effects on measures of quality of life, depressive symptoms, and well-being have
provided indirect evidence that hypoandrogenism could underlie these symptoms. The
results of this trial then would suggest that current mood symptoms, self-esteem, and quality
of life are not reflective of the androgen deficiency state present in women with POI. In a
previous study, we observed a higher than expected prevalence of a past history of major
depression in women with POI (42) suggesting that POI conveys a vulnerability to develop
depressive illness. The lack of therapeutic effects of T on depressive symptoms in these
women with POI does not rule out the possibility that testosterone deficiency contributes to
an underlying vulnerability to depressive illness. Thus it is possible that as with depression
during the natural menopause (43) abnormalities of T secretion could contribute to an
increased risk for depression. Moreover, a preventive effect of T replacement on the risk for
depression in these women remains a possible intervention to examine. Similarly, since
estrogen has reported antidepressant effects in women with perimenopausal depression (44;
45), it is also possible that the pre-study treatment with EPT reduced depressive symptoms
sufficiently to preclude any observable additional antidepressant effects of testosterone in
these women.
The findings of this study initially could appear to conflict with studies that have examined
the effects of T and EPT replacement (14; 37–41) or T alone (46; 47) on measures of sexual
dysfunction. There is considerable overlap in the items measured in most QOL scales and
the symptoms of both depression and decreased sexual function. Studies showing an
improvement in QOL or well-being after T treatment in hypogonadal women with sexual
dysfunction do not necessarily reflect a concurrent improvement in mood symptoms, nor can
the observed impact of T on mood and well-being be generalized to hypogonadal women
who do not have complaints of sexual dysfunction. Thus comparisons are less meaningful
across studies in which differing presenting symptoms are the targets of treatment. In this
study, in which women were recruited for a study of bone density, QOL measures could
reflect a range of phenomena unrelated to depressive symptoms, and depressive symptoms
would best be measured with specific depression rating scales and structured diagnostic
interviews. Since neither measures of depression nor QOL improved after EPT+T treatment
compared with EPT, our data suggests that in women with POI neither measure should be an
indication for T treatment in keeping with current Clinical Practice Guidelines (48).
The limitations in this study should be discussed. First, the presence of a small proportion of
women who met criteria for major depression prevents an adequate evaluation of the
antidepressant effects of T compared with placebo. This was a clinic-based sample not
selected for the presence or absence of depression and our sample reflected the profile of
symptoms encountered in a clinic-based practice more so than a sample selected for
psychiatric morbidity. While we did include women with depression, only eight women in
our study (approximately 12%) in the testosterone treatment arm met DSM criteria for major
depression (compared with a 12 month prevalence of 8.5% for major depression in the
general population of women (49)). The number of depressed women was not sufficiently
large to permit the demonstration of a beneficial effect of T on mood, particularly in the
context of concurrent EPT, which has demonstrated antidepressant effects (40; 41).
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However, to achieve 80% power in our analysis, we would need a sample size of 556
women with POI in each treatment arm for a total 1112 participants in the study in order to
demonstrate antidepressant effects - a sample size of depressed women prohibitively large to
ethically conduct an appropriately powered study of the antidepressant efficacy of T.
Moreover, as stated earlier this study was not designed to specifically evaluate the efficacy
of T as a treatment for depression. Nonetheless, a sample containing a larger proportion of
women with depressive symptoms could allow us to make a more definitive evaluation of
T’s mood elevating effects. Additionally, the concurrent use of antidepressant medication
could have obscured T’s potential antidepressant effects in those depressed women on
standard antidepressant medications. Finally, had we employed supraphysiologic doses of T
we may have identified a greater positive effect of T on quality of life measures or mood
symptoms.
Conclusion
Our data suggest that neither low self-esteem nor depressive symptoms are caused by low
androgen levels in women with POI (or improve with physiologic repletion of T). Moreover,
reports of decreased quality of life and self-esteem or the presence of depressive symptoms
could reflect a range of emotional stresses related to both the physiology of POI and the
impact of the diagnosis of POI on an individual woman independent of an underlying
gonadal steroid deficiency (both T and E2). There are important theoretical and practical
implications to our findings. The findings beg the question, “Does physiological ovarian
sex-hormone therapy in young women with primary ovarian insufficiency improve quality
of life and parameters of self-esteem and mood?” Despite the fact that normal ovarian
function provides menstruating women with a daily production of approximately 150
microgram of T, T replacement in these young women is not current standard of care (1).
We have demonstrated that the 150 microgram T patch does indeed achieve physiologic
hormone levels in women with POI with no significant increase in side effects or worsening
of mood compared to placebo. However, our findings suggest that T replacement has a non-
significant trend toward mood improvement in women with POI, suggesting that other
mechanisms might play a more significant role in the altered mood that may accompany this
disorder.
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Figure 1. Study population enrollment and outcomes
An initial sample of 395 women with POI was admitted to the NIH Clinical Center and
participated in the screening portion of the longer term study evaluating the effects on bone
health between July 2000 and February 2005. Eligibility was reported as the number of
women enrolled in the larger 3-year trial. Of these, 267 met exclusion criteria and 145 met
inclusion criteria and were enrolled in the larger study, of the 145 women randomized to T
or placebo treatment; 17 declined participation in the mood component of the study. Thus,
128 women with POI who were randomized to either T or placebo treatment were enrolled
in our study with 123 women completing the study. *Of the six women who had incomplete
ratings at the 12-month visit, two in the placebo arm and one in the T treatment arm had
incomplete behavior ratings (i.e., CES-D or HAM-D or SCID); the other three women,
present in the T treatment arm, completed the Q-Les-Q and one of those also completed the
SCID). Therefore, the completed data obtained from these women was included in the
analysis.
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Table 1
Baseline characteristics of women with POI randomized to T (n = 67) or placebo (n = 61)
Variable Testosterone Placebo P-value
Age (years) 31.1 (5.8) 32.1 (5.5) NS
BMI 23.4 (3.3) 24.2 (3.2) NS





Number on Thyroid therapy N = 5 N = 6 NS
CES-D ≥16 N= 15 (22.4%) N = 7 (11.7 %) NS
CES-D ≥8 and <16 N= 26 (38.8%) N= 23 (37.7%) NS
Current psychotropic medication usea N= 12 (18.5%) N= 11 (19.0%) NS
Past history of Axis I DXb N= 43 (64%) N= 42 (69%) NS
  MDE 33 (49%) 33 (54.1%)
  Minor Depression 8 (11.9%) 8 (13.1%)
  Dysthymia 1 (0.01%) 1 (0.02%)
  PTSD 1 (0.01%) None
SCID (current MDE) N= 8 (11.9%) N= 8 (13.1%) NS
SCID (current minor depression) N= 3 (4.5%) N= 7 (11.5%) NS
Baseline Free testosterone (ng/dl) 2.2 (1.4) 2.1(1.2) NS
Baseline Total testosterone (ng/dl) 21.7 (9.9) 18.7 (6.8) NS
Reported values are expressed as mean (SD) unless otherwise indicated. Eligible women met the following inclusion criteria: 1) diagnosis of
spontaneous 46, XX POI before the age of 40 yr (i.e. at least 4 months of oligomenorrhea or amenorrhea and FSH levels in the menopausal range,
as defined by laboratory confirmation on two separate occasions, at least 1 month apart); 2) age between 18 and 42; and 3) non-iatrogenic cause of
POI.
a
Current psychotropic medication use included citalopram, paroxetine, sertraline, and buproprion).
b
Past diagnoses and current depression were based on SCID scoring using DSM-IV diagnostic criteria for axis-I one mood disorders.
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Table 2
Outcome measures of symptom ratings at baseline, three months and twelve months. Unless otherwise
indicated, data are presented in means (SD).
Rating Scalea Testosterone [N=67] Placebo [N=61] P-valueb
Q-Les-Q
  Baseline 3.9 (0.7) [N=67] 4.0 (0.7) [N=61] 0.4
  3 months 4.3 (0.7) [N=67] 4.2 (0.7) [N=58] 0.3
  12 months 4.3 (0.7) [N=58] 4.2 (0.7) [N=57] 0.2
Rosenberg’s Self Esteem Scale
  Baseline 34.0 (5.3) [N=67] 34.7 (4.2) [N=61] 0.7
  3 months 35.8 (4.2) [N=67] 35.9 (4.3) [N=59] 0.8
  12 months 36.4 (3.7) [N=58] 36.3 (4.1) [N=58] 0.9
CES-D
  Baseline 10.7 (8.6) [N=67] 9.2 (7.8) [N=60] 0.3
  3 months 6.5 (5.4) [N=67] 6.6 (5.8) [N=60] 1.0
  12 months 5.9 (5.4) [N=58] 8.2 (8.5) [N=58] 0.4
HAM-D
  Baseline 9.5 (9.5) [N=67] 10.2 (8.8) [N=61] 0.4
  3 months 6.1 (6.4) [N=67] 6.4 (6.5) [N=59] 0.7
  12 months 5.1 (5.7) [N=57] 7.4 (8.1) [N=57] 0.1
SCID (reported as N (%) current depressed)
  Baseline 8 (12%) [N=67] 8 (13%) [N=61] 1.0
  3 months 6 (9.1%) [N=66] 5 (8.3%) [N=60] 1.0
  12 months 9 (15%) [N=59] 13 (22%) [N=59] 0.5
a
Scale scoring for the Q-Les-Q is 0–100 where higher numbers reflect increasing quality of life. Rosenberg’s self-esteem scale scoring is 10–40
with higher scores representing increased self-esteem. CES-D scores reflect depressive symptom severity using a scale range of 0–60 with higher
scores reflecting greater symptom severity (scores of 16 or higher are consistent with major depression). HAM-D scale scoring is based on a 21
item questionnaire with a score of 14 or higher consistent with moderate depression (higher scores are indicative of symptom severity (50). SCID
values represent the number of women who met DSM-IV criteria for a current MDE.
b
P-values presented were determined by Wilcoxon rank-sum tests in all outcome measures except the SCID, which was analyzed using Fisher’s
exact test.
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Table 3
Summary of side effects/adverse events between treatment groups at baseline, 3 months and 12 months,
reported as numbers of women with event (unless otherwise noted).
Event Measurea Baseline 3 months 12 months
Skin changesb
  Testosterone None 2 1
  Placebo 1 2 1
Hirsutismc
  Testosterone None None 1
  Placebo None None None
Acned
  Testosterone 5 7 5
  Placebo 2 4 2
Depilation Frequencye
  Testosterone 3 5 3
  Placebo 2 3 3
Dropped out due to side effects/ adverse eventsf
  Testosterone 2 (1.34%)
  Placebo None
a
P-values were > 0.05 for all comparisons.
b
Skin changes were reported as the number of episodes women experienced irritation, rash, or pigment changes during the course of treatment. The
reported skin changes did not require medical attention. One woman in each treatment group experienced localized skin darkening near the EPT
patch site.
c
Hirsutism was measured using the Ehrman scale scoring (51), where a code of 1 represents a score of 1–8 (normal) and a score > 8 is coded as a 2
(abnormal). Only abnormal hirsutism scores are reported (one woman in the T treatment group scored a 10 at 12 months).
d
Acne measurement represents a modified Cremonici scale scoring (52) where a score of 0–1 represents less than 10 acne pustules (normal) and a
score of 2–4 represents greater than 10 pustules (abnormal). Only the number of women who had abnormal acne scores is presented.
e
Depilation frequency is reported as the number of times in the past month that hair has been removed from lip or chin (range = 0–3). A score of 3
was reported as abnormal.
f
Reported adverse events at 3 months: two women withdrew from the study due to rash at the study patch site, neither of whom reported other
(androgenic) side effects as the basis for their decision to withdraw from the study.
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Table 4
Serum hormone levels between T treatment and Placebo in women with POI at baseline and after 3 and 12
months of treatment. Scores are presented in means (SD).
Variablea Baseline 3 months 12 months
Free Testosteroneb (pg/ml) reference range 1.3–6.8
  Testosterone 2.2 (1.4) [N=65] 4.7 (1.9) [N=63] 5.0 (3.4) [N=56]
  Placebo 2.1 (1.2) [N=59] 1.9 (0.9) [N=57] 1.6 (0.8) [N=54]
Total Testosteroneb (ng/dl) reference range 14–54.3
  Testosterone 21.7 (9.9) [N=66] 51.9 (20.1) [N=65] 49.6 (22.9) [N=56]
  Placebo 18.7 (6.8) [N=59] 17.5 (6.0) [N=57] 16.4 (5.8) [N=54]
Estradiol (pg/ml) reference range 34–225
  Testosterone 90.7 (58.1) [N=67] 111.1 (89.2) [N=67] 90.0 (67.3) [N=59]
  Placebo 100.5 (109.2) [N=61] 102.3 (85.2) [N=60] 91.7 (55.2) [N=59]
FSHc (IU/l) reference range 20–131
  Testosterone 24.9 (24.4) [N=67] 19.9 (18.6) [N=67] 20.0 (20.5) [N=59]
  Placebo 22.7 (24.2) [N=61] 17.5 (13.4) [N=60] 19.7 (16.3) [N=59]
LH (IU/l) reference range 2–49
  Testosterone 15.2 (13.7) [N=67] 12.6 (12.7) [N=67] 13.8 (13.7) [N=59]
  Placebo 14.6 (16.9) [N=61] 9.9 (8.8) [N=60] 11.9 (13.2) [N=59]
SHBG (nmol/l) reference range 40–120
  Testosterone 108.8 (51.8) [N=66] 110.4 (63.8) [N=67] 103.9 (45.5) [N=55]
  Placebo 95.3 (37.7) [N=59] 93.3 (42.3) [N=58] 96.9 (45.5) [N=54]
a
Reference ranges for total and free testosterone and SHBG correspond to Esoterix values, while those of estradiol, FSH, and LH correspond to the
NIH clinical center laboratory database.
b
P-values were < 0.001 in both free and total testosterone measures at 3and 12 months between treatment groups using Wilcoxon rank-sum tests.
P-values for all other serum hormone comparisons were > 0.05.
c
FSH levels represent study participation values when women were on EPT and do not reflect the diagnostic serum FSH levels (> 40 IU/l on two
occasions) obtained during screening, three months prior to study initiation when EPT was started.
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